EUCTR2015-003280-11-NL进行中（未招募）1 期
AN EXPLORATORY MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF THE SAFETY AND TOLERABILITY OF PIRFENIDONE (ESBRIET®) IN COMBINATION WITH NINTEDANIB (OFEV®) IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female, and age 40 through 80 years old
- •At the start of screening, on pirfenidone for at least 16 weeks and on a stable dose for at least 28 days (in this study, a stable dose will be defined as 1602–2403 mg/d); the dose must be expected to remain in that range throughout the study
- •Documented diagnosis of IPF, per the Investigator per using the criteria of the 2011 American Thoracic Society / European Respiratory Society / Japanese Respiratory Society / Latin American Thoracic Association guidelines
- •Pulmonary function test results at screening, percent predicted forced vital capacity (FVC) >=50% and percent predicted carbon monoxide diffusing capacity (DLco) >= 30%
- •For women of childbearing potential: agreement to remain abstinent or use two adequate methods of contraception, including at least one method with a failure rate of < 1% per year, during the treatment period and for at least 3 months after the final Follow-up Visit
- •For men: agreement to remain abstinent or use contraceptive measures and agreement to refrain from donating sperm during the treatment period and for at least for at least 3 months after the final Follow-up Visit
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 36
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 44
排除标准
- •- Clinical evidence of any active infection which according to the judgment of the investigator may interfere with study conduct measurement of pulmonary function, or impact the course of IPF
- •In the 28 days before the start of screening, any new or ongoing moderate or severe adverse reaction considered by the Investigator to be related to pirfenidone, or an pirfenidone treatment interruption > 7 days for any reason
- •Any condition that is likely to result in death in the 12 months after the start of screening
- •Lung transplantation anticipated in the 12 months after the start of screening
- •Known hypersensitivity to the active substance or any excipient of either pirfenidone or nintedanib
- •mild (Child Pugh A), moderate (Child Pugh B) or severe (Child Pugh C) hepatic impairment
- •Severe hepatic impairment, including end-stage liver disease
- •Severe renal impairment, including end-stage renal disease requiring dialysis
- •History or risk of gastrointestinal (GI) tract perforation
- •History of unstable or deteriorating cardiac or pulmonary disease in the 6 months before the start of screening
- •Electrocardiogram (ECG) with a heart-rate–corrected QT interval = 500 milliseconds (ms) at screening, or a family or personal history of long QT syndrome
- •Bleeding risk: genetic predisposition to bleeding, a haemorrhagic event in the 12 months before the start of screening, or abnormal laboratory coagulation parameters. Patients who require fibrinolysis, full-dose therapeutic anticoagulation, high-dose antiplatelet therapy, or other therapy that may substantially increase bleeding risk are excluded
- •Use of strong CYP1A2 inhibitors, inhibitors of P-glycoprotein or CYP3A4 or their inducers in the 28 days before the start of screening
- •History of alcohol or substance abuse in the 2 years before the start of screening
- •Use of any tobacco product in the 12 weeks before the start of screening, or an unwillingness to abstain from their use through the final Follow-up Visit
研究者
相似试验
进行中（未招募）
1 期
A Study of the Safety and Tolerability of Pirfenidone (Esbriet) in Combination with Nintedanib (Ofev) in Patients with Idiopathic Pulmonary FibrosisEUCTR2015-003280-11-ESRoche Farma S.A., que representa en España a F. Hoffmann-La Roche Ltd80
已完成
4 期
AN EXPLORATORY MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF THE SAFETY AND TOLERABILITY OF PIRFENIDONE (ESBRIET®) IN COMBINATION WITH NINTEDANIB (OFEV®) IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS10035597Idiopathic pulmonary fibrosispulmonary fibrosisNL-OMON43469Roche Nederland B.V.8
进行中（未招募）
1 期
A Study of the Safety and Tolerability of Pirfenidone (Esbriet) in Combination with Nintedanib (Ofev) in Patients with Idiopathic Pulmonary FibrosisEUCTR2015-003280-11-ITF. HOFFMANN - LA ROCHE LTD.89
进行中（未招募）
1 期
A Study of the Safety and Tolerability of Pirfenidone (Esbriet) in Combination with Nintedanib (Ofev) in Patients with Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)MedDRA version: 19.0Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-003280-11-DEF. Hoffmann-La Roche Ltd80
进行中（未招募）
1 期
A Study of the Safety and Tolerability of Pirfenidone (Esbriet) in Combination with Nintedanib (Ofev) in Patients with Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)MedDRA version: 19.0Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-003280-11-DKF. Hoffmann-La Roche Ltd80